Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2018 Sep 3. doi: 10.1038/s41418-018-0190-8. [Epub ahead of print]

PMID:
30177736
2.

Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.

Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM.

Cancer Cell. 2018 Aug 13;34(2):298-314.e7. doi: 10.1016/j.ccell.2018.07.004.

PMID:
30107178
3.

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.

Schulz-Heddergott R, Moll UM.

Cancers (Basel). 2018 Jun 7;10(6). pii: E188. doi: 10.3390/cancers10060188. Review.

4.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Mar;25(3):486-541. doi: 10.1038/s41418-017-0012-4. Epub 2018 Jan 23. Review.

5.

Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism.

Nemajerova A, Amelio I, Gebel J, Dötsch V, Melino G, Moll UM.

Cell Death Differ. 2018 Jan;25(1):144-153. doi: 10.1038/cdd.2017.178. Epub 2017 Oct 27. Review.

6.

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.

Alexandrova EM, Xu S, Moll UM.

Cell Death Dis. 2017 Mar 16;8(3):e2683. doi: 10.1038/cddis.2017.108.

7.

p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo.

Alexandrova EM, Mirza SA, Xu S, Schulz-Heddergott R, Marchenko ND, Moll UM.

Cell Death Dis. 2017 Mar 9;8(3):e2661. doi: 10.1038/cddis.2017.80.

8.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

9.

Depleting stabilized GOF mutant p53 proteins by inhibiting molecular folding chaperones: a new promise in cancer therapy.

Alexandrova EM, Moll UM.

Cell Death Differ. 2017 Jan;24(1):3-5. doi: 10.1038/cdd.2016.145. Epub 2016 Dec 9. No abstract available.

10.

Mdm2 as a chromatin modifier.

Wienken M, Moll UM, Dobbelstein M.

J Mol Cell Biol. 2017 Feb 1;9(1):74-80. doi: 10.1093/jmcb/mjw046. Review.

11.

Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2017 Feb;24(2):300-316. doi: 10.1038/cdd.2016.124. Epub 2016 Nov 11. Erratum in: Cell Death Differ. 2018 Sep 3;:.

12.

Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin.

Brocks T, Fedorchenko O, Schliermann N, Stein A, Moll UM, Seegobin S, Dewor M, Hallek M, Marquardt Y, Fietkau K, Heise R, Huth S, Pfister H, Bernhagen J, Bucala R, Baron JM, Fingerle-Rowson G.

FASEB J. 2017 Feb;31(2):526-543. doi: 10.1096/fj.201600860R. Epub 2016 Oct 19.

13.

A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems.

Lebedev I, Nemajerova A, Foda ZH, Kornaj M, Tong M, Moll UM, Seeliger MA.

J Mol Biol. 2016 Oct 9;428(20):4154-4167. doi: 10.1016/j.jmb.2016.08.001. Epub 2016 Aug 8.

14.

TAp73 is a central transcriptional regulator of airway multiciliogenesis.

Nemajerova A, Kramer D, Siller SS, Herr C, Shomroni O, Pena T, Gallinas Suazo C, Glaser K, Wildung M, Steffen H, Sriraman A, Oberle F, Wienken M, Hennion M, Vidal R, Royen B, Alevra M, Schild D, Bals R, Dönitz J, Riedel D, Bonn S, Takemaru K, Moll UM, Lizé M.

Genes Dev. 2016 Jun 1;30(11):1300-12. doi: 10.1101/gad.279836.116. Epub 2016 Jun 2.

15.

MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.

Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M.

Mol Cell. 2016 Jan 7;61(1):68-83. doi: 10.1016/j.molcel.2015.12.008. Epub 2015 Dec 31.

16.

Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15720. Epub 2015 Sep 30. No abstract available.

PMID:
26416737
17.

MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP.

Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M.

Mol Cell. 2015 Jul 16;59(2):243-57. doi: 10.1016/j.molcel.2015.05.036. Epub 2015 Jul 2.

18.

Expansion of the hematopoietic stem cell compartment is necessary but not sufficient for gain-of-function mutant p53 R248Q to accelerate lymphomagenesis.

Yallowitz AR, Hanel W, Moll UM.

Cell Death Differ. 2015 Aug;22(8):1397. doi: 10.1038/cdd.2015.63. Epub 2015 Jun 5. No abstract available.

19.

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM.

Nature. 2015 Jul 16;523(7560):352-6. doi: 10.1038/nature14430. Epub 2015 May 25. Erratum in: Nature. 2015 Nov 19;527(7578):398.

20.

p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state.

Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, Moll UM, Lowe SW, Cartegni L, Sordella R.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3287-96. doi: 10.1073/pnas.1321640111. Epub 2014 Jul 29.

21.

Mitochondrial death functions of p53.

Marchenko ND, Moll UM.

Mol Cell Oncol. 2014 Oct 31;1(2):e955995. doi: 10.1080/23723548.2014.955995. eCollection 2014 Apr-Jun. Review.

22.

TAp73 is essential for germ cell adhesion and maturation in testis.

Holembowski L, Kramer D, Riedel D, Sordella R, Nemajerova A, Dobbelstein M, Moll UM.

J Cell Biol. 2014 Mar 31;204(7):1173-90. doi: 10.1083/jcb.201306066. Epub 2014 Mar 24.

23.

Cortical hypoplasia and ventriculomegaly of p73-deficient mice: Developmental and adult analysis.

Medina-Bolívar C, González-Arnay E, Talos F, González-Gómez M, Moll UM, Meyer G.

J Comp Neurol. 2014 Aug 1;522(11):2663-79. doi: 10.1002/cne.23556. Epub 2014 Apr 3.

PMID:
24500610
24.

p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis.

Yallowitz AR, Alexandrova EM, Talos F, Xu S, Marchenko ND, Moll UM.

Cell Death Differ. 2014 Apr;21(4):645-54. doi: 10.1038/cdd.2013.199. Epub 2014 Jan 17.

25.

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM.

Cell Death Dis. 2014 Jan 2;5:e980. doi: 10.1038/cddis.2013.508.

26.

p53 further extends its reach.

Zirngibl K, Moll UM.

Oncoimmunology. 2013 May 1;2(5):e24959. No abstract available.

27.

Targeting the heat shock protein 90: a rational way to inhibit macrophage migration inhibitory factor function in cancer.

Schulz R, Moll UM.

Curr Opin Oncol. 2014 Jan;26(1):108-13. doi: 10.1097/CCO.0000000000000036. Review.

PMID:
24225413
28.

ΔNp63 regulates select routes of reprogramming via multiple mechanisms.

Alexandrova EM, Petrenko O, Nemajerova A, Romano RA, Sinha S, Moll UM.

Cell Death Differ. 2013 Dec;20(12):1698-708. doi: 10.1038/cdd.2013.122. Epub 2013 Sep 6.

29.

Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial F₁F0-ATP synthase.

Bergeaud M, Mathieu L, Guillaume A, Moll UM, Mignotte B, Le Floch N, Vayssière JL, Rincheval V.

Cell Cycle. 2013 Sep 1;12(17):2781-93. doi: 10.4161/cc.25870. Epub 2013 Aug 6.

30.

p73 - constitutively open for business.

Seeliger MA, Moll UM.

Cell Death Differ. 2013 Aug;20(8):972-3. doi: 10.1038/cdd.2013.56. No abstract available.

31.

Direct reprogramming by oncogenic Ras and Myc.

Ischenko I, Zhi J, Moll UM, Nemajerova A, Petrenko O.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3937-42. doi: 10.1073/pnas.1219592110. Epub 2013 Feb 19.

32.

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates.

Schulz R, Dobbelstein M, Moll UM.

Oncoimmunology. 2012 Nov 1;1(8):1425-1426.

33.

Generation of p53-deficient induced pluripotent stem cells from mouse embryo fibroblasts.

Alexandrova EM, Moll UM.

Methods Mol Biol. 2013;962:157-64. doi: 10.1007/978-1-62703-236-0_13.

PMID:
23150445
34.

Identification of p53 in mitochondria.

Vaseva AV, Moll UM.

Methods Mol Biol. 2013;962:75-84. doi: 10.1007/978-1-62703-236-0_6.

PMID:
23150438
35.

p73 is dispensable for commitment to neural stem cell fate, but is essential for neural stem cell maintenance and for blocking premature differentiation.

Alexandrova EM, Talos F, Moll UM.

Cell Death Differ. 2013 Feb;20(2):368. doi: 10.1038/cdd.2012.134. Epub 2012 Oct 26. No abstract available.

36.

p53 opens the mitochondrial permeability transition pore to trigger necrosis.

Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM.

Cell. 2012 Jun 22;149(7):1536-48. doi: 10.1016/j.cell.2012.05.014.

37.

Two-factor reprogramming of somatic cells to pluripotent stem cells reveals partial functional redundancy of Sox2 and Klf4.

Nemajerova A, Kim SY, Petrenko O, Moll UM.

Cell Death Differ. 2012 Aug;19(8):1268-76. doi: 10.1038/cdd.2012.45. Epub 2012 Apr 27.

38.

Role of p53 family members p73 and p63 in human hematological malignancies.

Alexandrova EM, Moll UM.

Leuk Lymphoma. 2012 Nov;53(11):2116-29. doi: 10.3109/10428194.2012.684348. Epub 2012 May 21. Review.

PMID:
22497596
39.

Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM.

J Exp Med. 2012 Feb 13;209(2):275-89. doi: 10.1084/jem.20111117. Epub 2012 Jan 23. Erratum in: J Exp Med. 2012 Mar 12;209(3):640.

40.

Links between mutant p53 and genomic instability.

Hanel W, Moll UM.

J Cell Biochem. 2012 Feb;113(2):433-9. doi: 10.1002/jcb.23400. Review.

41.

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.

Li D, Marchenko ND, Moll UM.

Cell Death Differ. 2011 Dec;18(12):1904-13. doi: 10.1038/cdd.2011.71. Epub 2011 Jun 3.

42.

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.

Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM.

Cell Death Dis. 2011 May 12;2:e156. doi: 10.1038/cddis.2011.39.

43.

Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.

Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM.

Mol Cancer Res. 2011 May;9(5):577-88. doi: 10.1158/1541-7786.MCR-10-0534. Epub 2011 Apr 8.

44.

Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes.

Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3624-9. doi: 10.1073/pnas.1016201108. Epub 2011 Feb 7.

45.

p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis.

Talos F, Abraham A, Vaseva AV, Holembowski L, Tsirka SE, Scheel A, Bode D, Dobbelstein M, Brück W, Moll UM.

Cell Death Differ. 2010 Dec;17(12):1816-29. doi: 10.1038/cdd.2010.131.

46.

Role of the p53 family in stabilizing the genome and preventing polyploidization.

Talos F, Moll UM.

Adv Exp Med Biol. 2010;676:73-91. Review.

PMID:
20687470
47.

Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice.

Nemajerova A, Petrenko O, Trümper L, Palacios G, Moll UM.

J Clin Invest. 2010 Jun;120(6):2070-80. doi: 10.1172/JCI40331. Epub 2010 May 17.

48.

p63 and canonical Wnt signaling.

Talos F, Schulz R, Moll UM.

Cell Cycle. 2010 Feb 15;9(4):648-9. Epub 2010 Feb 15. No abstract available.

PMID:
20190579
49.

Brdm2 - an aberrant hypomorphic p63 allele.

Talos F, Wolff S, Beyer U, Dobbelstein M, Moll UM.

Cell Death Differ. 2010 Jan;17(1):184-186. No abstract available.

50.

BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain.

Hagn F, Klein C, Demmer O, Marchenko N, Vaseva A, Moll UM, Kessler H.

J Biol Chem. 2010 Jan 29;285(5):3439-50. doi: 10.1074/jbc.M109.065391. Epub 2009 Dec 2.

Supplemental Content

Support Center